Fludarabine with cytarabine followed by reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation in patients with poor-risk chronic lymphocytic leukemia

Annals of Hematology

Volumn 92, Issue 2, 2013, Pages 249-254

  Krejci, Marta ^a   Doubek, Michael ^a,b   Brychtova, Yvona ^a   Stehlikova, Olga ^a   Chovancova, Jana ^a   Tichy, Boris ^a,b   Francova, Hana Skuhrova ^a   Navratil, Milan ^a   Tomiska, Miroslav ^a   Horky, Ondrej ^a   Pospisilova, Sarka ^a,b   Mayer, Jiri ^a,b  

^a UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^b MASARYK UNIVERSITY   (Czech Republic)

Author keywords

Chronic lymphocytic leukemia; Cytarabine; Fludarabine; Reduced intensity conditioning

Indexed keywords

CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; FLUDARABINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; THYMOCYTE ANTIBODY;

ADULT; ADVERSE OUTCOME; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BRONCHOPNEUMONIA; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER RISK; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; DONOR LYMPHOCYTE INFUSION; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG OVERDOSE; ENGRAFTMENT; FEBRILE NEUTROPENIA; FEMALE; FLOW CYTOMETRY; FOLLOW UP; GASTROINTESTINAL DISEASE; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; MALE; MUCOSA INFLAMMATION; MULTIPLE ORGAN FAILURE; NEUTROPHIL; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SEPSIS; WHOLE BODY RADIATION;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW TRANSPLANTATION; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KAPLAN-MEIER ESTIMATE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; NEOPLASM, RESIDUAL; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PREDNISOLONE; PROSPECTIVE STUDIES; RECURRENCE; RISK; SALVAGE THERAPY; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; VIDARABINE; VINCRISTINE; WHOLE-BODY IRRADIATION;

EID: 84872324740     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-012-1579-y     Document Type: Article

References (29)

1. Ljungman P, Bregni M, Brune M, Cornelissen J, de Witte T, Dini G et al (2010) Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009. Bone Marrow Transplant 45:219-234
2. Dreger P, Corradini P, Kimby E, Michallet M, Miligan D, Schetelig J et al (2007) Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus. Leukemia 21:12-17
3. Dreger P, Dohner H, Ritgen M, Bottcher S, Busch R, Dietrich S et al (2010) Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German Study Group CLL3X trial. Blood 116:2438-2447
4. Doubek M, Mayer J, Obrtlikova P, Smolej L, Cmunt E, Schvarz J et al (2011) Modern and conventional prognostic markers of chronic lymphocytix leukaemia in the everyday haematological practice. Eur J Haematol 87:130-137
5. Valkova V, Schwarz J, Vitek A, Markova M, Polhreich D, Benesova K et al (2011) The effect of allogeneic stem cell transplantation on high risk chronic lymphocytic leukaemia: a single centre retrospective analysis. Hematol Oncol 29:22-30
6. Khouri IF, Saliba RM, Admirand J et al (2007) Graft-versus-leukaemia effect after non-myeloablative haematopoetic transplantation can overcome the unfavourable expression of ZAP-70 in refractory chronic lymphocytic leukaemia. Br J Haematol 137:355-363
7. Sorror ML, Storer BE, Sandmaier BM et al (2008) Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. J Clin Oncol 26:4912-4920
8. Brown JR, Kim HT, Li S et al (2006) Predictors of improved progression-free survival after nonmyeloablativne allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia. Biol Blood Marrow Transplant 12:1056-1064
9. Schmid C, Schleuning M, Ledderose G et al (2005) Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol 23:5675-5687
10. Krejci M, Brychtova Y, Doubek M, Toskova M, Racil Z, Koristek Z et al (2011) Efficacy and toxicity of the FLAMSA/RIC regimen in 40 patients with high-risk AML: a single centre experience. Haematologica 93(S2):411-412 (abstract 0987)
11. Gandhi V, Kemera A, Keating MJ, Plunket W (1992) Fludarabine infusion potentiates arabinosylcytosine metabolism in lymphocytes of patients with chronic lymphocytic leukemia. Cancer Res 52:897-903
12. Tsimberidou AM, Wierda WG, Plunkett W et al (2008) Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patiens with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 26:196-203
13. Krüger WH, Bohlius J, Cornely OA, Einsele H, Hebart H, Massenkeil G et al (2005) Antimicrobial prophylaxis in allogeneic bone marrow transplantation. Guidelines of the Infectious Disease Working Party (AGIHO) of the German Society of Haematology and Oncology. Ann Oncol 16:1381-1390
14. Przepiorka D, Weisdorf D, Martin P et al (1995) Consensus conference on acute GVHD grading. Bone Marrow Transplant 15:825-828
15. Shulman HM, Sullivan KM, Weiden PL et al (1980) Chronic graft-versus-host syndrome in man. A long-term clinicopatologic study of 20 Seattle patients. Am J Med 60:204-217
16. Hallek M, Cheson BD, Catovsky D et al (2008) Gudelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on chronic lymphocytic leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 111:5446-5456
17. Ritgen M, Böttcher S, Stilgenbauer S et al (2008) Quantitative MRD monitoring identifies distinct GVL response patterns after allogeneic stem cell transplantation for chronic lymphocytic leukemia: results from the GCLLSG CLL3X trial. Leukemia 22:1377-1386
18. Lion T (2003) Summary: reports on quantitative analysis of chimerim after allogeneic stem cell transplantation by PCR amplification of microsatellite markers and capillary electrophoresis with fluorescence detection. Leukemia 17:232-254
19. Horky O, Mayer J, Kablaskova L, Razga F, Krejci M, Kissova J et al (2011) Increasing hematopoietic microchimerism is a reliable indicator of incipient AML relapse. Int J Hematol 33:57-66
20. Rawstron AC, Villamor N, Ritgen M et al (2007) International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia. Leukemia 21:956-964
21. Zohren F, Czibere A, Bruns I et al (2009) Fludarabine, amsacrine, high-dose cytarabine and 12 Gy total body irradiation followed by allogeneic hematopoietic stem cell transplantation is effective in patients with relapsed or high-risk acute lymphoblastic leukemia. Bone Marrow Transplant 44:1-8
22. Delgado J, Thomson K, Russel N et al (2006) Results of alemtuzumab-based reduced intensity allogeneic transplantation for chronic lymphocytic leukemia: a British Society of Blood and Marrow Transplantation study. Blood 107:1724-1730
23. Delgado J, Miligan DW, Dreger P (2009) Allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia: ready for primetime? Blood 114:2581-2588
24. Schmidt C, Schleuning M, Schwerdtfeger R et al (2006) Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation. Blood 108:1092-1099
25. Banna GL, Aversa S, Sileni VC, Favaretto A, Ghiotto C et al (2004) Nonmyeloablative allogeneic stem cell transplantation (NST) after truly nonmyeloablative and reduced intensity conditioning regimens. Crit Rev Oncol Hematol 51:171-189
26. Finke J, Bethge WA, Schmoor C et al (2009) Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomized, open-label, multicentre phase 3 trial. Lancet Oncol 10:855-864
27. Dreger P, Brand R, Milligan D et al (2005) Reduced-intensity conditioning lowers treatment-relapted mortality of allogeneic stem cell transplantation for chronic lymphocytic leukemia: a population-matched analysis. Leukemia 19:1029-1033
28. Farina L, Carniti C, Doredo A et al (2009) Qualitative and quantitative polymerase chain reaction monitoring of minimal residual duseiase in relaposed chronic lymphocytic leukemia: early assesment can predict long-term outcome after reduced intensity allogeneic transplantation. Haematologica 94:654-662
29. Moreno C, Villamor N, Esteve J et al (2006) Clinical significance of minimal residual disease, as assessed by different techniques, after stem cell transplantation for chronic lymphocytic leukemia. Blood 107:1563-4569